Compare Incyte Corporation (INCY) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs SMX Security Matters plc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while SMX Security Matters plc trades at $18.25 (market cap $16.38M). The key difference: Incyte Corporation is far larger — about 1410.9× SMX Security Matters plc's market cap, and Incyte Corporation is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| INCY | SMX | |
|---|---|---|
Market Cap | $23.11B | $16.38M |
Sector | Health | Technology |
52-Week High | $118.52 | $295.56K |
52-Week Low | $67.38 | $12.87 |
Enterprise Value | $19.13B | $13.35M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SMX trades at $17.66, up 6.9% today, with neutral technical signals and bearish moving averages. The stock shows a P/B of 1.85 but negative profitability metrics, including a -2,216.26% ROE. Recent news highlights balance sheet strengthening and commercialization progress in recycled materials tracking technology, amid regulatory tailwinds for verified plastics.
Outlook hinges on execution of global strategy and policy-driven demand, but high financial losses and reverse stock splits signal substantial risk. Investor sentiment is cautious despite positive media coverage on industry positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
